

# Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





# Anaplastic Large Cell Lymphoma FISH Panel

#### **Alternative Name**

ALCL, Peripheral T-cell lymphoma (PTCL)

### Methodology

**FISH** 

# **Test Description**

**Probes:** ALK (2p23) | TP63 (3q28) | TBL1XR1/TP63 [inv(3)(q26q28)] | DUSP22-IRF4 (6p25.3) Probes may be ordered separately except TP63 (3q28) and TBL1XR1/TP63 [inv(3)(q26q28)] are performed combined and reported as co-dependent for result and interpretation of TP63 rearrangement status.

Disease(s): Anaplastic Large Cell Lymphoma (ALCL), peripheral T-cell lymphoma (PTCL)

## **Clinical Significance**

The ALCL FISH Panel is used for the detection of recurrent chromosome abnormalities observed in patients with anaplastic large cell lymphoma (ALCL) which may classify those patients into specific risk groups. This panel includes ALK (2p23) rearrangement testing. Patients with ALK-positive ALCL have a favorable prognosis compared to ALK-negative ALCL patients. This panel also includes two assays to detect TP63 rearrangements. Rearrangements of the TP63 gene encoding p63 fusion defines a subset of ALK-negative ALCL cases and are associated with aggressive course and poor outcome as compared to peripheral T-cell lymphoma without these rearrangements. The TBL1XR1/TP63 fusion [inv(3)] has also been reported in rare cases of peripheral T-cell lymphoma NOS, mycosis fungoides, diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. This panel also includes the DUSP22-IRF4 rearrangement test which has been reported in CD30-positive, ALK-negative ALCL and is associated with favorable clinical outcome. DUSP22-IRF4 rearrangements have been also reported in patients with lymphomatoid papulosis (LyP).

### **Specimen Requirements**

- Bone Marrow Aspirate: N/A Peripheral Blood: N/A
- Fresh, Unfixed Tissue: N/A
- Fluids: N/A
- Paraffin Block: H&E slide (required) plus paraffin block. Circle H&E for tech-only.
- Cut Slides: H&E slide (required) plus 4 unstained slides cut at 4 microns. Circle H&E for tech only.

# **Storage & Transportation**

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

# CPT Code(s)\*

88374x4 automated or 88377x4 manual

#### **New York Approved**

Yes

#### **Level of Service**

Technical, Global

#### **Turnaround Time**

3-5 days

#### References

- 1. Pederson MB, Hamilton Dutoit SJ, Bendix K, et al. DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. *Blood*. 2017; 130:554-557.
- 2. Parrilla Castellar ER, Jaffe ES, Said JS, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. *Blood*. 2014; 124:1473-1480.
- 3. Wada DA, Law ME, Hsi ED, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. *Mod Pathol.* 2011; 24:596-605.
- Peterson JF, Pearce KE, Meyer RG, et al. Fluorescence in-situ hybridisation for TP63 rearrangements in T cell lymphomas: single-site experience of 470 patients and implications for clinical testing. *Histopathology*. 2020;76(3):481-485. PMID: 31557339.

Please direct any questions regarding coding to the payor being billed.

<sup>\*</sup>The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way Fort Myers, FL 33912

Phone: 239.768.0600/ Fax: 239.690.4237

neogenomics.com

© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved. All other trademarks are the property of their respective owners

Rev. 052024